ONDINE BIOMEDICAL INC. (OBI) — Half Year Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the ONDINE BIOMEDICAL INSTATATION. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time by the q and a tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. And I'd now like to hand you over to Nicholas Labelle. Good afternoon, sir. Good afternoon. Thank you so much, Lily. Thank you to all investors and attendees of our mid year results corporate update for 2024. We start by reminding folks on this call that every year, there are nine Wembley Stadium full of people who get a hospital acquired infection. This is a horrible statistic. This is something that shouldn't be there at all. There should be zero hospital acquired infections, but they are unfortunately a fact of life in today's world. And and those infections, excuse me, are so significant that they produce an enormous added burden to the cost of health care. And this is in all countries, but in The UK, you're looking at a 2,000,000,000 plus pound expense and over five and a half million bed days utilized for these infections. Put that in context, we have a 6,000,000 patient waiting backlog of folks in the NHS, the longest in history. And to double that with another six million days needed to treat these infections is really serious problem. We need to get on top of this, and, unfortunately, the current approach, is using empirical antibiotics, isn't working well as resistance starts t...